According to Iovance Biotherapeutics 's latest financial reports the company's total liabilities are A$0.30 Billion. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2024-12-31 | A$0.32 B | 11.93% |
2023-12-31 | A$0.28 B | 18.96% |
2022-12-31 | A$0.24 B | 12.47% |
2021-12-31 | A$0.21 B | 47.47% |
2020-12-31 | A$0.14 B | 123.15% |
2019-12-31 | A$65.24 M | 214.24% |
2018-12-31 | A$20.76 M | 63.88% |
2017-12-31 | A$12.67 M | 83.84% |
2016-12-31 | A$6.89 M | 208.03% |
2015-12-31 | A$2.23 M | 10.18% |
2014-12-31 | A$2.03 M | -20.2% |
2013-12-31 | A$2.54 M | -76.7% |
2012-12-31 | A$10.92 M | -16.12% |
2011-12-31 | A$13.01 M | 1507.15% |
2010-12-31 | A$0.81 M | 3047.54% |
2009-12-31 | A$0.02 M | 445.61% |
2008-12-31 | A$0 M |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
![]() NRC Health
NRC | A$0.16 B | -46.95% | ๐บ๐ธ USA |
![]() Nymox Pharmaceutical NYMX | A$4.8 M | -98.42% | Bahamas |